Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
Employees: 11-50
Total raised: $7.8M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | New Scienc... | newscience... |
| - | Easton Cap... | eastoncapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.11.2012 | Series B | $5.8M | - |
| 17.05.2011 | Series A | $2M | - |
Mentions in press and media 6
| Date | Title | Description |
| 01.11.2012 | Resolve Therapeutics Raises $5.8M Series B | SEATTLE, WA, Company has raised $5.8 million in a Series B private-equity financing. The financing was led by previous investor New Science Ventures. >> Click here for more funding data on Resolve Therapeutics >> To export R... |
| 01.11.2012 | New anti-interferon alpha therapy for lupus nabs $5.8M, could start clinical trials next year | With the new money, Resolve will be able to advance its investigational lupus compound into clinical trials, which are expected to start in mid-2013, CEO James Posada said in a statement. The compound is currently in IND-enabling studies. S... |
| 01.11.2012 | Resolve Therapeutics Raises $5.8M in Series B Financing | Resolve Therapeutics, a Seattle, WA-based biotechnology company, has raised $5.8m in Series B financing. The round was led by existing investor New Science Ventures, with participation of new investor WRF Capital and previous investor Easto... |
| 01.11.2012 | Resolve Therapeutics lands $5.8M to crack the code on Lupus | Resolve Therapeutics, a 2-year-old Seattle biotechnology spin off from the University of Washington, has raised $5.8 million in new financing from New Science Ventures, WRF Capital and Easton Capital. The company will use the funds to conti... |
| 17.05.2011 | Resolve Therapeutics Raises $2M in Series A Financing | Resolve Therapeutics, LLC, a Seattle, WA-based biotechnology company focused on lupus therapy, has raised $2m in the first close of a Series A financing. Investors include New Science Ventures and Easton Capital. Led by CEO James Posada, Re... |
| - | New anti-interferon alpha therapy for lupus nabs $5.8M, could start clinical trials next year | The approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug approvals for the autoimmune disease lupus that had lasted more than half a century. A lengthy pipeline of drugs is hoping to follow suit... |